Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
STOK Stock Summary
Top 10 Correlated ETFs
STOK
In the News
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
Triple Threat: 3 Stocks to Buy for 3X Upside Potential
You want speculative stocks with upside potential up to 3X returns? I'm going to give them to you.
Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?
The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
New Strong Buy Stocks for February 14th
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 6:45 p.m. ET (3:45 p.m. PT). A live audio webcast of the presentation will be available on the Investors & News section of Stoke's website.
STOK Financial details
STOK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.32 | |
Net income per share | -0.53 | -1.59 | -1.51 | -2.31 | -2.39 | |
Operating cash flow per share | -0.47 | -1.73 | -1.26 | -1.82 | -0.82 | |
Free cash flow per share | -0.51 | -1.82 | -1.29 | -1.85 | -0.92 | |
Cash per share | 4.48 | 12.38 | 8.58 | 5.98 | 5.9 | |
Book value per share | 4.47 | 12.49 | 8.54 | 5.93 | 4.75 | |
Tangible book value per share | 4.47 | 12.49 | 8.54 | 5.93 | 4.75 | |
Share holders equity per share | 4.47 | 12.49 | 8.54 | 5.93 | 4.75 | |
Interest debt per share | 0 | 0 | 0.03 | 0.04 | 0.14 | |
Market cap | 601.2M | 508.95M | 2.07B | 881.38M | 359.02M | |
Enterprise value | 495.8M | 286.48M | 1.79B | 737.99M | 247.83M | |
P/E ratio | -48.01 | -17.84 | -40.98 | -10.4 | -3.86 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 28.94 | |
POCF ratio | -54.83 | -16.39 | -49.12 | -13.17 | -11.27 | |
PFCF ratio | -50.52 | -15.57 | -47.93 | -12.94 | -10.02 | |
P/B Ratio | 5.72 | 2.27 | 7.25 | 4.05 | 1.94 | |
PTB ratio | 5.72 | 2.27 | 7.25 | 4.05 | 1.94 | |
EV to sales | 0 | 0 | 0 | 0 | 19.98 | |
Enterprise value over EBITDA | -39.45 | -8.03 | -33.68 | -8.57 | -2.37 | |
EV to operating cash flow | -45.22 | -9.22 | -42.32 | -11.03 | -7.78 | |
EV to free cash flow | -41.67 | -8.76 | -41.29 | -10.84 | -6.92 | |
Earnings yield | -0.02 | -0.06 | -0.02 | -0.1 | -0.26 | |
Free cash flow yield | -0.02 | -0.06 | -0.02 | -0.08 | -0.1 | |
Debt to equity | 0 | 0 | 0 | 0.01 | 0.01 | |
Debt to assets | 0 | 0 | 0 | 0.01 | 0.01 | |
Net debt to EBITDA | 8.39 | 6.24 | 5.41 | 1.67 | 1.07 | |
Current ratio | 43.03 | 55.12 | 25.73 | 13.37 | 7.77 | |
Interest coverage | 0 | 0 | 0 | -717.21 | -33.43 | |
Income quality | 0.88 | 0.96 | 0.81 | 0.78 | 0.32 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 3.14 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 6.27 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.09 | 0.05 | 0.02 | 0.02 | 0.12 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.32 | |
Capex to depreciation | -4.37 | -3.63 | -1.18 | -1.23 | -2.56 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 1.84 | |
Graham number | 7.32 | 21.12 | 17.04 | 17.54 | 16 | |
ROIC | -0.12 | -0.14 | -0.18 | -0.38 | -0.51 | |
Return on tangible assets | -0.12 | -0.12 | -0.17 | -0.35 | -0.36 | |
Graham Net | 4.38 | 12.15 | 8.23 | 5.41 | 4.22 | |
Working capital | 103.68M | 221.93M | 282.51M | 212.08M | 212.68M | |
Tangible asset value | 105.07M | 224.43M | 286.08M | 217.78M | 184.85M | |
Net current asset value | 103.67M | 221.71M | 282.08M | 208.13M | 172.85M | |
Invested capital | 0 | 0 | 0 | 0.01 | 0.01 | |
Average receivables | 98K | 238.5K | 143.5K | 69K | 360K | |
Average payables | 606K | 911K | 1.12M | 1.94M | 1.58M | |
Average inventory | 0 | 0 | 0 | 0 | 5.47M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 17.3 | |
Days payables outstanding | 0 | 609.14 | 283.32 | 390.37 | 79.09 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 1.13K | |
Receivables turnover | 0 | 0 | 0 | 0 | 21.1 | |
Payables turnover | 0 | 0.6 | 1.29 | 0.94 | 4.61 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0.32 | |
ROE | -0.12 | -0.13 | -0.18 | -0.39 | -0.5 | |
Capex per share | -0.04 | -0.09 | -0.03 | -0.03 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.07 | 0.08 | 0.12 | -0.06 | 0.07 | |
Net income per share | -0.61 | -0.56 | -0.43 | -0.69 | -0.55 | |
Operating cash flow per share | -0.56 | -0.57 | -0.5 | -0.49 | -0.39 | |
Free cash flow per share | -0.61 | -0.58 | -0.51 | -0.51 | -0.4 | |
Cash per share | 6.38 | 5.82 | 5.96 | 5.24 | 4.85 | |
Book value per share | 5.18 | 4.69 | 5.03 | 4.3 | 3.91 | |
Tangible book value per share | 5.18 | 4.69 | 5.03 | 4.3 | 3.91 | |
Share holders equity per share | 5.18 | 4.69 | 5.03 | 4.3 | 3.91 | |
Interest debt per share | 0.08 | 0.1 | 0.11 | 0.11 | 0.12 | |
Market cap | 506.16M | 363.98M | 354.33M | 469.72M | 174.41M | |
Enterprise value | 395.07M | 252.78M | 166.39M | 280.11M | -13.07M | |
P/E ratio | -5.26 | -4.13 | -4.84 | -3.83 | -1.78 | |
Price to sales ratio | 174.24 | 111.34 | 68.78 | -189.33 | 52.72 | |
POCF ratio | -22.95 | -16.27 | -16.59 | -21.55 | -10.1 | |
PFCF ratio | -21.01 | -15.98 | -16.46 | -20.75 | -9.88 | |
P/B Ratio | 2.48 | 1.97 | 1.66 | 2.47 | 1.01 | |
PTB ratio | 2.48 | 1.97 | 1.66 | 2.47 | 1.01 | |
EV to sales | 136 | 77.33 | 32.3 | -112.9 | -3.95 | |
Enterprise value over EBITDA | -14.76 | -9.3 | -6.74 | -8.42 | 0.48 | |
EV to operating cash flow | -17.91 | -11.3 | -7.79 | -12.85 | 0.76 | |
EV to free cash flow | -16.4 | -11.1 | -7.73 | -12.37 | 0.74 | |
Earnings yield | -0.05 | -0.06 | -0.05 | -0.07 | -0.14 | |
Free cash flow yield | -0.05 | -0.06 | -0.06 | -0.05 | -0.1 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 4.15 | 4.09 | 7.61 | 5.7 | 6.88 | |
Current ratio | 9.19 | 7.77 | 8.57 | 11.28 | 9.13 | |
Interest coverage | -27.28 | -18.37 | -9.72 | -12.96 | -10.27 | |
Income quality | 0.84 | 0.87 | 0.95 | 0.71 | 0.7 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.42 | 2.87 | 1.98 | -4.12 | 3.1 | |
Research and developement to revenue | 6.92 | 6.44 | 3.81 | -8.28 | 6.13 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.09 | 0.02 | 0.01 | 0.04 | 0.02 | |
Capex to revenue | -0.7 | -0.13 | -0.03 | 0.34 | -0.12 | |
Capex to depreciation | -5.23 | -0.67 | -0.28 | -1.37 | -0.6 | |
Stock based compensation to revenue | 2.04 | 1.77 | 1.14 | -2.72 | 1.98 | |
Graham number | 8.44 | 7.68 | 6.98 | 8.2 | 6.98 | |
ROIC | -0.12 | -0.12 | -0.08 | -0.15 | -0.13 | |
Return on tangible assets | -0.09 | -0.09 | -0.06 | -0.12 | -0.1 | |
Graham Net | 4.53 | 4.17 | 4.49 | 3.85 | 3.46 | |
Working capital | 235.81M | 212.68M | 238.71M | 224.4M | 204.82M | |
Tangible asset value | 204.14M | 184.85M | 213.82M | 190.2M | 173M | |
Net current asset value | 191.12M | 172.85M | 202.26M | 179.51M | 163.13M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Average receivables | 372.5K | 491.5K | 540K | 314K | 116K | |
Average payables | 2.76M | 1.34M | 2.53M | 2.93M | 2.32M | |
Average inventory | 0 | 5.47M | 10.56M | 10.57M | 10.94M | |
Days sales outstanding | 12.24 | 16.19 | 8.59 | -4.93 | 2.61 | |
Days payables outstanding | 186.14 | 59.84 | 337.32 | 120 | 230.7 | |
Days of inventory on hand | 0 | 854.06 | 799.64 | 844.47 | 820.2 | |
Receivables turnover | 7.35 | 5.56 | 10.47 | -18.24 | 34.46 | |
Payables turnover | 0.48 | 1.5 | 0.27 | 0.75 | 0.39 | |
Inventory turnover | 0 | 0.11 | 0.11 | 0.11 | 0.11 | |
ROE | -0.12 | -0.12 | -0.09 | -0.16 | -0.14 | |
Capex per share | -0.05 | -0.01 | 0 | -0.02 | -0.01 |
STOK Frequently Asked Questions
What is Stoke Therapeutics, Inc. stock symbol ?
Stoke Therapeutics, Inc. is a US stock , located in Bedford of Ma and trading under the symbol STOK
Is Stoke Therapeutics, Inc. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $31.5. The lowest prediction is $21 and the highest is $58
What is STOK stock prediction ?
With a median analyst target price of $21.5, 2 stock analysts have made 2 forecasts in last 90 days. $21 is the lowest and $22 is the greatest projection.
What is Stoke Therapeutics, Inc. stock quote today ?
Stoke Therapeutics, Inc. stock price is $13.5 today.
Is Stoke Therapeutics, Inc. stock public?
Yes, Stoke Therapeutics, Inc. is a publicly traded company.